Dr. Sandeep Sahay, MD
NPI: 1669602710
Total Payments
$366,850
2024 Payments
$56,192
Companies
22
Transactions
772
Medicare Patients
1,516
Medicare Billing
$271,304
Payment Breakdown by Category
Other$166,240 (45.3%)
Consulting$145,053 (39.5%)
Travel$30,665 (8.4%)
Food & Beverage$22,104 (6.0%)
Research$2,548 (0.7%)
Education$240.13 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $166,240 | 101 | 45.3% |
| Consulting Fee | $145,053 | 64 | 39.5% |
| Travel and Lodging | $30,665 | 136 | 8.4% |
| Food and Beverage | $22,104 | 440 | 6.0% |
| Unspecified | $2,548 | 16 | 0.7% |
| Education | $240.13 | 15 | 0.1% |
Payments by Type
General
$364,302
756 transactions
Research
$2,548
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| United Therapeutics Corporation | $121,741 | 239 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $112,474 | 246 | $0 (2024) |
| Merck Sharp & Dohme LLC | $64,102 | 101 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $62,952 | 106 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,705 | 20 | $0 (2024) |
| Bayer Healthcare LLC | $915.00 | 1 | $0 (2023) |
| Actelion Pharmaceuticals, Ltd | $787.26 | 9 | $0 (2020) |
| Gilead Sciences, Inc. | $360.77 | 17 | $0 (2019) |
| Genentech USA, Inc. | $229.13 | 7 | $0 (2020) |
| Sandoz Inc. | $146.48 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $56,192 | 126 | Merck Sharp & Dohme LLC ($42,958) |
| 2023 | $59,804 | 120 | Merck Sharp & Dohme LLC ($20,779) |
| 2022 | $44,105 | 77 | United Therapeutics Corporation ($21,751) |
| 2021 | $22,683 | 26 | United Therapeutics Corporation ($16,198) |
| 2020 | $37,509 | 48 | United Therapeutics Corporation ($15,397) |
| 2019 | $55,893 | 157 | Actelion Pharmaceuticals US, Inc. ($27,255) |
| 2018 | $56,255 | 128 | Actelion Pharmaceuticals US, Inc. ($25,294) |
| 2017 | $34,409 | 90 | Bayer HealthCare Pharmaceuticals Inc. ($20,884) |
All Payment Transactions
772 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: Respiratory | ||||||
| 12/11/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $76.91 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 12/09/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $103.74 | General |
| 12/07/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $48.06 | General |
| Category: Cardiology | ||||||
| 12/02/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,627.50 | General |
| 11/25/2024 | United Therapeutics Corporation | ORENITRAM (Drug) | Food and Beverage | In-kind items and services | $104.64 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 11/25/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $6.79 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 11/21/2024 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $135.13 | General |
| 11/20/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $3.54 | General |
| Category: Cardiology | ||||||
| 10/31/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $112.22 | General |
| Category: Cardiology | ||||||
| 10/30/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Consulting Fee | Cash or cash equivalent | $697.50 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/30/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: Respiratory | ||||||
| 10/21/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $9.61 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 10/21/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $2.81 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 10/17/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $9.10 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 10/15/2024 | United Therapeutics Corporation | — | Consulting Fee | Cash or cash equivalent | $3,480.00 | General |
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 09/30/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Travel and Lodging | In-kind items and services | $413.40 | General |
| Category: Cardiology | ||||||
| 09/20/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/20/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $59.99 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/20/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/19/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $529.72 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/19/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $304.07 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/19/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $269.55 | General |
| Category: CARDIOVASCULAR | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso | United Therapeutics Corporation | $1,163 | 10 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 311 | 527 | $168,320 | $50,249 |
| 2022 | 9 | 400 | 741 | $248,847 | $70,265 |
| 2021 | 9 | 386 | 820 | $272,249 | $82,909 |
| 2020 | 9 | 419 | 832 | $250,781 | $67,882 |
Total Patients
1,516
Total Services
2,920
Medicare Billing
$271,304
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 62 | 216 | $65,232 | $20,455 | 31.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 74 | 102 | $32,946 | $10,776 | 32.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 84 | 113 | $25,990 | $7,807 | 30.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 41 | 44 | $25,872 | $6,038 | 23.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 17 | 17 | $8,330 | $2,378 | 28.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 15 | 15 | $5,730 | $1,516 | 26.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 20 | $4,220 | $1,278 | 30.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 76 | 287 | $86,674 | $22,754 | 26.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 102 | 162 | $37,260 | $12,458 | 33.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 57 | 67 | $39,396 | $10,402 | 26.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 56 | 71 | $22,933 | $8,437 | 36.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 12 | 46 | $30,883 | $7,606 | 24.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 33 | 33 | $12,606 | $3,163 | 25.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 35 | 45 | $9,495 | $2,544 | 26.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 15 | 15 | $7,350 | $2,137 | 29.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 14 | 15 | $2,250 | $764.23 | 34.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 60 | 316 | $95,432 | $26,706 | 28.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 121 | 190 | $43,700 | $15,034 | 34.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 68 | 110 | $35,530 | $13,329 | 37.5% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 13 | 59 | $38,586 | $10,662 | 27.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 43 | 56 | $32,928 | $9,145 | 27.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 27 | 27 | $10,314 | $3,264 | 31.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 31 | 39 | $8,229 | $2,298 | 27.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 12 | 12 | $5,880 | $1,899 | 32.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 11 | 11 | $1,650 | $571.54 | 34.6% |
About Dr. Sandeep Sahay, MD
Dr. Sandeep Sahay, MD is a Student in an Organized Health Care Education/Training Program healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/23/2009. The National Provider Identifier (NPI) number assigned to this provider is 1669602710.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sandeep Sahay, MD has received a total of $366,850 in payments from pharmaceutical and medical device companies, with $56,192 received in 2024. These payments were reported across 772 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($166,240).
As a Medicare-enrolled provider, Sahay has provided services to 1,516 Medicare beneficiaries, totaling 2,920 services with total Medicare billing of $271,304. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Internal Medicine, Critical Care Medicine
- Location Houston, TX
- Active Since 07/23/2009
- Last Updated 11/30/2016
- Taxonomy Code 390200000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1669602710
Products in Payments
- Adempas (Drug) $62,830
- UPTRAVI (Drug) $42,189
- ORENITRAM (Drug) $41,474
- TYVASO (Drug) $22,876
- OPSUMIT (Drug) $20,591
- NONE (Drug) $14,553
- WINREVAIR (Biological) $13,694
- REMODULIN (Drug) $3,404
- OFEV (Drug) $2,679
- BOSENTAN (Drug) $1,935
- OPSUMIT MACITENTAN (Drug) $636.34
- Esbriet (Biological) $229.13
- TREPROSTINIL (Drug) $146.48
- Non-Covered (Drug) $122.27
- Arikayce (Drug) $108.93
- AVYCAZ (Drug) $58.11
- Repatha (Biological) $49.67
- CRESEMBA (Drug) $41.90
- GENERAL - VASCULAR INTERVENTION (Device) $26.29
- DUPIXENT (Biological) $20.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Houston
Diego Marines Copado, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $287,975
Student in an Organized Health Care Education/Training Program $287,975
Dr. Eddie Patton, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $235,342
Student in an Organized Health Care Education/Training Program $235,342
Naveen Pemmaraju, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $198,556
Student in an Organized Health Care Education/Training Program $198,556
Laila Tabatabai, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $194,524
Student in an Organized Health Care Education/Training Program $194,524
Syed Naqvi, M.d./M.b.a, M.D./M.B.A
Student in an Organized Health Care Education/Training Program — Payments: $144,401
Student in an Organized Health Care Education/Training Program $144,401
Sheetal Shroff, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $99,679
Student in an Organized Health Care Education/Training Program $99,679